medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2008, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2008; 55 (1)

Updating in the antimicrobial susceptibility of microorganisms causals of respiratory infections in ambulatory patients

Barriga AG, Arumir EC, Mercado GNF

Language: Spanish
References: 37
Page: 29-36
PDF size: 110.95 Kb.


ABSTRACT

Objective: To evaluate the in vitro activity of twelve antimicrobial agents against 600 bacterial strains isolated from the same number of outpatients with respiratory infections. Material and methods: A prospective study was conducted in the bacterial strains isolated from outpatients with acute respiratory infections from La Raza Medical Center (IMSS) using a microdilution method and determine minimal inhibitory concentrations 50 and 90. Results: Clarithromycin was the most active of the twelve antimicrobials evaluated, with the lowest minimal inhibitory concentrations and the lowest resistance, most of the strains show resistance to fluoroquinolones; we do not find Streptococcus pyogenes strains resistant to Clarithromycin. Streptococcus pneumoniae was the most frequent etiological agent isolated and with the highest minimal inhibitory concentration as and percents of resistance. Conclusions: Clarithromycin was the antimicrobial of first election for the treatment of active respiratory infections in outpatients.


REFERENCES

  1. Camarillo RMS. Pathogens and acute respiratory distress syndrome. México. Salud Publica Mex 2007; 49 (1): 1-2.

  2. Soriano V, Granizo JJ, Coronel P, Gimeno M, Rodenas E et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. Int Jour Antimicrob Agen 2004: 23 (3): 295-298.

  3. Lipsitch MP. How do antimicrobial agents lead to resistance in pathogens causing acute respiratory tract infections. Infect Dis Clin Pract 2006: 14: 56-510.

  4. Sistema Nacional de Evaluación: Tercera vigilancia de los progresos en la aplicación de estrategias de salud para todos en el año 2000, SPT/2000. México, D. F.: INEGI/DGEIE, 1994.

  5. Lopardo HA, Hernández C, Vidal P. Resistencia de Streptococcus pyogenes a los antibióticos. Experiencia de once años en un hospital pediátrico de Buenos Aires. Acta Bioquím Clin Latinoam 2004; 38 (2): 1-9.

  6. Ciftci E, Dogru U, Gurís H, Derya HA, Ince E. Antibiotic susceptibility of Streptococcus pyogenes strains isolates from throat cultures of children with tonsillopharyngitis. Journal Ankara Medical School 2003; 25 (1): 15-20.

  7. Piedrola DM, Montiel NQ, Lopez RI, Monje VE, Casado MJC et al. Situación actual de las resistencias a antibióticos en infecciones amigdalares. Acta Otorrinolaringol Esp 2006; 57: 171-175.

  8. Doern GV, Pfaller MA, Klugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratoty tract isolates of Streptococcus pneumoniae in North America: 1997. Results from the SENTRY Antimicrobial Surveillance Program. Clin Infec Dis 1998; 27: 764-770.

  9. Goosesens H. Surveillance of resistance among major pathogens causing respiratory tract infections in the United States. Infect Dis Clin Pract 2006; 14: 52-55.

  10. Verdium CM, Hol C, Fleer A, Van Dih H, Belkum A. Moraxella catarrhalis: from emerging to established pathogen. Clin Microb Rev 2002; 1 (15): 125-144.

  11. Doern CV, Jones RN, Pfaller MF, Kugler K. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired. Respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program. Antim Ag Chem 1999 ; 43 (2): 385-389.

  12. Weber TJ. Appropriate use of antimicrobial drugs a better prescription is needed. JAMA 2005; 294 (18): 2354-2356.

  13. González PAA, Ortiz ZC, Mota UR, Dickinson GE, Dávila MR, Fernández OMA. Sensibilidad antimicrobiana y caracterización de cepas de Streptococcus pyogenes aisladas de un brote de escarlatina. Salud Publica Mex 2002; 44 (5): 437-441.

  14. Soriano VS, Brasili S, Saiz M, Carranza C, Vidal P, Calderoni J, Lopardo H. Streptococcus pyogenes: sensibilidad a penicilina y eritromicina en las ciudades de Neuguen y Cipolletti. Medicina (Buenos Aires) 2000; 60 (4): 487-490.

  15. Tristram S, Jacobs M, Appelbaun P. Antimicrobial Resistance in Haemophilus influenzae. Clin Microb Rev 2007; 20 (2): 368-389.

  16. Walker ES, Neal CL, Laffan E, Kalbtleish JH, Berk SL, Levy T. Long term trends in susceptibility of Moraxella catarrhalis; a population analysis. Journ Antim Chem 2000; 45 (2): 175-182.

  17. Deshpande LM, Sader HS, Tritscke TR, Jones RN. Contemporary prevalence of BRO B-lactamases in Moraxella catarrhalis. Report from the SENTRY. Antimicrobial Surveillance Program (North America, 1997-2004). Journ Clin Microb 2006; 4 (10): 3775-3777.

  18. Morrisey I, Tillotson G. Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus Influenzae. Journ Antimic Chemoth 2004; 53:144-148.

  19. Sader HS, Jones RN. Cefdinir; an oral cephalosporin for the treatment of respiratory tract infection and skin structure infections. Expert Rev Anti Infec Ther 2007; 5 (1): 29-43.

  20. Lee MY, Kok S, Oh WS, Parks SY, Lee JY et al. In vitro activity of Cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Int J Antimicrob Agents 2006; 28 (1): 14-18.

  21. Sader HS, Fritsche TP, Mutnick PH, Jones RN. Contemporary evaluation of the in vitro activity and spectrum of Cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens. (2000-2002). Diagn Microbiol Infect Dis 2003; 47 (3): 515-525.

  22. Jones RN, Biedenbach DJ, Croco MA, Barrett MS. In vitro evaluation of a novel orally, administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1998; 31 (4): 573-578.

  23. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. 2007; M100-17, 27, 1.

  24. Scriver SR, Low DE, Simur AE, Toye B, Mc Greer A, Jaeger R. Broth microdilution testing of Haemophilus test medium versus lysed horse blood broth. Canadian Haemophilus Study Group. Journ Clin Micro 1992; 30 (9): 2284-2289.

  25. Turnidgee J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microb Rev 2007; 20 (3): 391-408.

  26. Fitoussi F, Cohen R, Brain G, Dost C, Brahimi N, de la Rocque F. Molecular DNA analysis for differentiation of persistence or relapse from recurrence in treatment failure of Streptococcus pyogenes pharyngitis. Eur J Clin Microbiol Infect Dis 1997; 16: 233-237.

  27. King DE, Malorie R, Lilley SH. New classification and update on the quinolone antibiotics. Americ Fam Phys 2000; 61 (9): 2741-2778.

  28. Ritcher SS, Diekema DJ, Heilmann KP, Almer LS, Shortridge UP et al. Fluoroquinolone Resistance in Streptococcus pyogenes. Antimicrobial Agents and Chemotherapy 2006; 50 (3): 943-948.

  29. Ranin L, Opauski O, Djukic S, Mijac V. Epidemiology of diseases caused by Streptococcus pyogenes in Serbia during a nine year period. Indian J Med Rev 2004; 119: (suppl).155-159.

  30. Brook I. The role of beta-lactamase producing bacteria in the persistence of streptococcal tonsillar pharyngitis. Rev Infect Dis 1984; 6: 601-607.

  31. Berg HF, Jeroen HT, Scheffer GJ, Peeters MT, Keulen PHJ et al. Emergence and resistance of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow release clarithromycin; a randomized double-blind, placebo controlled study. Antimicrob Agen Chemoth 2004; 48 (11): 4183-4188.

  32. Ho PL, Yung RWH, Tsang DNC, Pue TJ, Ho M, Sato WH. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones; results of Hong Kong multicentre study in 2000. J Antimicrob Chem 2001; 48: 659-665.

  33. Chen DK, Mc Gear A, de Azabedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-239.

  34. Hutchinsen J. Resistance to levofloxacin and failure of treatment of Pneumococcal pneumoniae. N Engl J Med 2002: 347 (1): 66-67.

  35. Stein GE, Schooley S, Tyrrell KL, Citron DM, Ellie J, Goldstein C. Bactericidal activities of methoxy fluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob Agents Chemother 2003; 47 (4): 1308-1312.

  36. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005; 118: 259-260.

  37. Fuchs PC, Barry AL, Brown SP. Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin. Jour Clin Microbiol 2001; 39 (1): 43-46.




2020     |     www.medigraphic.com